Skip to main content
SpringerLink
Log in

A Review of Calcium Channel Antagonists in the Treatment of Pediatric Hypertension

  • Review Article
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

All children aged ≥3 years should have an annual blood pressure (BP) measurement taken during a routine physical examination. Physicians should become familiar with recommended pediatric normative BP tables. BP above the 95th percentile may require drug therapy. There are several categories of antihypertensives available to the clinician. Calcium channel antagonists (CCAs) are a class of drugs that exert their antihypertensive effect by inhibiting the influx of calcium ions across the cell membranes. This results in dilatation of peripheral arterioles. When given orally, CCAs are metabolised in the liver by cytochrome P450 (CYP) enzyme CYP3A4; hence, some CCAs will affect the half-life of drugs that share this enzyme system for their metabolism. CCAs can be safely used in children with renal insufficiency or failure and as a general rule there is no need to modify drug dosage in this population. CCAs are generally well tolerated; most adverse effects appear to be dose related. Headache, flushing, gastrointestinal upset, and edema of the lower extremities are the most common symptoms reported with the use of CCAs. Pediatric data regarding safety and efficacy of CCAs have mostly been obtained from retrospective analyses. Extended-release nifedipine and amlodipine are the two most commonly used oral CCAs in the management of pediatric hypertension. These drugs can be given once a day, although many children require twice-daily administration.

Extended-release nifedipine has to be swallowed whole; hence, its use in younger children who cannot swallow pills is limited. Amlodipine can be made into a solution without compromising its long duration of action; therefore, it is the CCA of choice for very young children. Oral short-acting nifedipine and intravenous nicardipine are safe and effective CCAs for the management of hypertensive crisis in children. Short-acting nifedipine can cause unpredictable changes in BP; hence, it should be used cautiously and in low doses. Intravenous nicardipine has a rapid onset of action and a short half-life. Intravenous infusion of nicardipine can be titrated for effective control of BP. Intravenous nicardipine has been used safely in hospitalized children and newborns for the management of hypertensive crisis, and for controlled hypotension during surgery.

CCAs are a class of antihypertensives that are safe and effective in pediatric patients. They have relatively few adverse effects and are well tolerated by children. This article reviews CCAs as antihypertensives in the management of pediatric hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. National High Blood Pressure Education Program Working Group report on hypertension control in children and adolescents. Update on the 1987 task force report on high blood pressure in children and adolescents. Pediatrics 1996; 98: 649–58

    Google Scholar 

  2. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997; 157: 2413–46

    Google Scholar 

  3. Zimmer SH, Levy PS, Kass EH. Familial aggregation of blood pressure in childhood. N Engl J Med 1971; 284: 401–4

    Article  Google Scholar 

  4. Shear CL, Burke GL, Freedman DS, et al. Value of childhood blood pressure measurements and family history in predicting future blood pressure status: results of 8 years of follow up in Bogalusa Heart Study. Pediatrics 1986; 77: 862–9

    PubMed  CAS  Google Scholar 

  5. Jung FF, Inglefinger JR. Hypertension in childhood and adolescence. Pediatr Rev 1993; 14: 169–79

    Article  PubMed  CAS  Google Scholar 

  6. American Academy of Pediatrics. Recommendations for preventive pediatric health care (RE 9535). Pediatrics 1995; 96: 1–6

    Google Scholar 

  7. National Heart, Lung, and Blood Institute. Report of the Second Task Force on blood pressure control in children. Pediatrics 1987; 79: 1–25

    Google Scholar 

  8. National Heart, Lung, and Blood Institute. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents [online]. Available from URL: http://www.nhlbi.nih.gov/health/prof/heart/hbp/hbp_ped.htm [Accessed 2006 Jun 28]

  9. Lieberman E. Hypertension in childhood and adolescence. In: Kaplan NM, editor. Clinical hypertension. Baltimore (MD): Williams and Wilkins, 1998: 407–20

    Google Scholar 

  10. Sinaiko AR. Treatment of hypertension in children. Pediatr Nephrol 1994; 8: 603–9

    Article  PubMed  CAS  Google Scholar 

  11. Rocchini AP, Key J, Bondie D, et al. The effect of weight loss on the sensitivity of blood pressure in obese adolescents. N Engl J Med 1989; 321: 580–5

    Article  PubMed  CAS  Google Scholar 

  12. Falkner B, Sadowski RH. Hypertension in children and adolescents. Am J Hypertens 1995; 6: 106S–10S

    Article  Google Scholar 

  13. Rocchini AP, Katch V, Anderson J, et al. Blood pressure in obese adolescents: effect of weight loss. Pediatrics 1988; 82: 16–23

    PubMed  CAS  Google Scholar 

  14. Flynn JT. Pediatric use of antihypertensive medications. Curr Ther Res 2001; 62: 314–28

    Article  CAS  Google Scholar 

  15. Bauer JH, Reams P, editors. Brenner and Rector’s. 6th ed. Angiotensin-converting enzyme inhibitors. Philadelphia (PA): W.B. Saunders, 2000: 2270

  16. Gavras I. Bradykinin mediated effects of ACE inhibitors. Kidney Int 1992; 42: 1020–9

    Article  PubMed  CAS  Google Scholar 

  17. Kostis JB. Angiotensin-converting enzyme inhibitors. Am J Hypertens 1989; 2: 57–64

    PubMed  CAS  Google Scholar 

  18. Williams GH. Converting enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988; 319: 1517–25

    Article  PubMed  CAS  Google Scholar 

  19. Heeg JE, de Jong PE, van der Hem GK, et al. Reduction of proteinuria by angiotensin converting enzyme inhibition. Kidney Int 1987; 32: 78–83

    Article  PubMed  CAS  Google Scholar 

  20. De Zeeuw D, Heeg JE, Stelwagen T, et al. Mechanism of antiproteinuric effect of angiotensin-converting enzyme inhibition. Contrib Nephrol 1990; 83: 160–5

    PubMed  Google Scholar 

  21. Giatras I, Lau J, Levey A. Effect of angiotensin converting enzyme inhibitors on the progression of non-diabetic renal disease: a meta-analysis of randomized trials. Ann Int Med 1997; 127: 337–45

    PubMed  CAS  Google Scholar 

  22. Lavie CJ, Ventura HO, Messeril FH. Regression of increased left ventricular mass by antihypertensives. Drugs 1991; 42: 945–61

    Article  PubMed  CAS  Google Scholar 

  23. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 725–7

    Article  Google Scholar 

  24. Pfeffer M, Braunwald E, Moye L, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement trial. N Engl J Med 1992; 327: 669–77

    Article  PubMed  CAS  Google Scholar 

  25. The seventh report on the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–72

    Google Scholar 

  26. Gazdick LP, Maxwell M, Ruff D, et al. A double-blind, randomized, parallel, active-controlled study to evaluate the antihypertensive efficacy and safety of losartan in patients with severe hypertension [abstract]. Am J Hypertens 1994; 7 (Pt 2): 100A

    Google Scholar 

  27. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptor antagonists. N Engl J Med 1996; 334: 1645–9

    Google Scholar 

  28. Azizi M, Guyene TT, Chatellier G, et al. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 1997; 29: 634–40

    Article  PubMed  CAS  Google Scholar 

  29. Miller K, Aitken B, Rodel Jr PV, et al. Enalapril, a well tolerated and efficacious agent for the pediatric hypertensive patient. J Cardiovasc Pharmacol 1987; 10: S154–6

    Article  PubMed  Google Scholar 

  30. Mirkin BL, Newman TJ. Efficacy and safety of captopril in the treatment of severe childhood hypertension: report of the International Collaborative Study Group. Pediatrics 1985; 75: 1091–100

    PubMed  CAS  Google Scholar 

  31. O’Dea RF, Mirkin BL, Alward CT, et al. Treatment to neonatal hypertension with captopril. J Pediatr 1988; 113: 403–6

    Article  PubMed  Google Scholar 

  32. Tack ED, Perlman JM. Renal failure in sick hypertensive premature infants receiving captopril therapy. J Pediatr 1988; 112: 805–10

    Article  PubMed  CAS  Google Scholar 

  33. Wells TG, Bunchman TE, Kearns GL. Treatment of neonatal hypertension with enalaprilat. J Pediatr 1990; 117: 664–7

    Article  PubMed  CAS  Google Scholar 

  34. Jafar TH, Pereira JG. A cautionary note for nephrologists: is it time to abandon the use of dihydropyridine calcium channel blockers? (editorial). Semin Dialysis 1999; 12(3): 137–9

    Article  Google Scholar 

  35. Tobe S, Epstein M. The use of calcium antagonists in the treatment of hypertensive persons with kidney disease. Curr Hypertens Reports 2000; 4: 191–4

    Article  Google Scholar 

  36. Griffin KA, Bidani AK. Calcium-channel blockers and the progression of renal disease. Curr Hypertens Reports 1999; 1: 436–45

    Article  CAS  Google Scholar 

  37. Griffin KA, Picken MM, Bakris GI, et al. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int 1999; 55: 1849–60

    Article  PubMed  CAS  Google Scholar 

  38. Ruggenti P, Perna A, Benini R, et al. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. J Am Soc Nephrol 1998; 9: 2096–101

    Google Scholar 

  39. Hayashi K, Ozawa Y, Fujiwara K, et al. Role of actions of calcium antagonist on efferent arterioles: with special references to glomerular hypertension. Am J Nephrol 2003; 23(4): 229–44

    Article  PubMed  CAS  Google Scholar 

  40. Triggs DL. Mechanisms of action of calcium channel antagonists: calcium antagonists in clinical medicine. Philadelphia (PA): Hanley and Belfus, 1–26

  41. Toyo-Oka T, Nayler WG. Third generation calcium entry blockers. Blood Press 1996; 5: 206–8

    Article  PubMed  CAS  Google Scholar 

  42. Luscher TF, Cosentino F. The classification of calcium antagonists and their selection in the treatment of hypertension: a reappraisal. Drugs 1998; 55: 509–17

    Article  PubMed  CAS  Google Scholar 

  43. Drug facts and comparisons: updated monthly. St Louis (MO): Wolters Kluwer, Sep 2002: 438–45

  44. Baeulis V. Antiproteinuric effect of verapamil in children with glomerulonephritis [abstract]. Pediatr Nephrol 2000; 14: C64

    Google Scholar 

  45. Bauer JH, Reams G. Short and long term effects of calcium entry blockers on the kidney. Am J Cardiol 1987; 59: 66A–71A

    Article  PubMed  CAS  Google Scholar 

  46. Kloke HL, Branten AJ, Huysmans FT, et al. Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers. Kidney Int 1998; 53: 1559–73

    Article  PubMed  CAS  Google Scholar 

  47. Weidman P, Schneider M, Bohlen L. Therapeutic efficacy of different antihypertensive drugs in diabetic nephropathy. Nephrol Dial Transplant 1955; Suppl. 9: 39–45

    Google Scholar 

  48. Harper SJ, Moorhouse J, Abrams K, et al. The beneficial effects of oral nifedipine on cyclosporine treated renal transplant recipients. Transplant Int 1996; 9: 115–25

    Article  CAS  Google Scholar 

  49. Radicio JL. Calcium antagonists and renal protection from cyclosporine nephrotoxicity: long term trial in renal transplantation patients. J Cardiovasc Pharmacol 2000; 35: S7–11

    Article  Google Scholar 

  50. Flynn JT, Pasko DA. Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. Pediatr Nephrol 2000; 15: 302–16

    Article  PubMed  CAS  Google Scholar 

  51. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18: 84–112

    PubMed  CAS  Google Scholar 

  52. Dougall HT, McLay JA. Comparative review of the adverse effects of calcium antagonists. Drug Safety 1996; 15: 91–106

    Article  PubMed  CAS  Google Scholar 

  53. Meraw SJ, Sheridan PJ. Medically induced gingival hyperplasia. Mayo Clin Proceed 1998; 73: 1196–9

    Article  CAS  Google Scholar 

  54. Westbrook P, Bednarczyk EM, Carlson M, et al. Regression of nifedipine-induced gingival hyperplasia following switch to a same class calcium channel blocker, isradipine. J Periodontol 1997; 68: 645–50

    Article  PubMed  CAS  Google Scholar 

  55. Silverstein DM, Palmer J, Baluarte HJ, et al. Use of calcium channel blockers in pediatric renal transplant recipients. Pediatr Trans 1999; 3: 88–92

    Google Scholar 

  56. Flynn JT, Warnick SJ. Isradipine treatment of hypertension in children: a single-center experience. Pediatr Nephrol 2002; 17: 748–53

    Article  PubMed  Google Scholar 

  57. Tallian KB, Nahata MC, Turman MA, et al. Efficacy of amlodipine in pediatric patients with hypertension. Pediatr Nephrol 1999; 13: 304–10

    Article  PubMed  CAS  Google Scholar 

  58. Von Vigier RO, Franscini LMD, Bianda NDF, et al. Antihypertensive efficacy of amlodipine in children with chronic kidney diseases. J Human Hypertens 2001; 15: 387–91

    Article  CAS  Google Scholar 

  59. Wyeth Pharmaceuticals Inc. Diltiazem [product information]. Morgantown (WV): Wyeth Pharmaceuticals Inc, Jan 2005

    Google Scholar 

  60. Buckley MMT, Grant SM, Goa KL, et al. Diltiazem: a reappraisal of its pharmacological properties and therapeutic use. Drugs 1990; 39: 757–806

    Article  PubMed  CAS  Google Scholar 

  61. Porter CJ, Carson A, Gillette PC. Verapamil: an effective calcium channel blocking agent for pediatric patients. Pediatrics 1983; 71: 748–55

    PubMed  CAS  Google Scholar 

  62. PUREPAC Pharmaceutical Company. Nifedipine capsules [product information]. Elizabeth (NJ): PUREPAC Pharmaceutical Company, Jul 2004

    Google Scholar 

  63. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620–5

    Article  PubMed  CAS  Google Scholar 

  64. Grossman E, Messerli FH, Grodzicki T, et al. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? Arch Intern Med 1990; 150: 686–7

    Article  Google Scholar 

  65. Leavitt AD, Zweifler AL. Nifedipine, hypotension, and myocardial injury. Ann Intern Med 1988; 108: 305–6

    Google Scholar 

  66. Nobile-Orazio E, Sterzai R. Cerebral ischaemia after nifedipine treatment (case report). Br Med J (Clin Res Ed) 1981; 283(6297): 948

    Article  CAS  Google Scholar 

  67. Cherney D, Straus S. Management of patients with hypertensive urgencies and emergencies. J Gen Intern Med 2002; 17: 937–45

    Article  PubMed  Google Scholar 

  68. Dilmen U, Caglar MK, Senses DA, et al. Nifedipine in hypertensive emergencies of children. Am J Dis Child 1983; 137: 1162–5

    PubMed  CAS  Google Scholar 

  69. Roth B, Herkenrath P, Krebber J, et al. Nifedipine in hypertensive crises of infants and children. Clin Exp Hypertens 1986; 89: 871–7

    Article  Google Scholar 

  70. Evans JH, Shaw NJ, Brocklebank JT. Sublingual nifedipine in acute severe hypertension. Arch Dis Child 1988; 63: 975–7

    Article  PubMed  CAS  Google Scholar 

  71. Lopez-Herce J, Albajara L, Garcia S, et al. Treatment of hypertensive crises in children with nifedipine. Int Care Med 1988; 14: 519–21

    Article  CAS  Google Scholar 

  72. Siegler RL, Brewer E. Effect of sublingual or oral nifedipine in the treatment of hypertension. J Pediatr 1988; 112: 811–3

    Article  PubMed  CAS  Google Scholar 

  73. Gauthier B, Trachtman H. Short-acting nifedipine [letter]. Pediatr Nephrol 1997; 11: 786–7

    PubMed  CAS  Google Scholar 

  74. Truttman AC, Zehnder-Schlapbach S, Bianchetti MG. A moratorium should be placed on the use of short acting nifedipine for hypertensive crises [letter]. Pediatr Nephrol 1998; 12: 259–61

    Google Scholar 

  75. Wells TG, Graham CJ, Moss MM, et al. Nifedipine poisoning in a child. Pediatrics 1990; 86: 91–4

    PubMed  CAS  Google Scholar 

  76. Sasaki R, Hirota K, Masuda A. Nifedipine induced transient cerebral ischemia in a child with Cockayne syndrome [letter]. Anaesthesia 1997; 52: 1236

    PubMed  CAS  Google Scholar 

  77. Spizzirri F, Rahman R. Adverse reactions to short acting nifedipine in hypertensive crises [letter]. Pediatr Nephrol 1999; 13: 366

    PubMed  CAS  Google Scholar 

  78. Leonard MB, Kasner SE, Feldman HI, et al. Adverse neurological events associated with rebound hypertension after using short-acting nifedipine in childhood hypertension. Pediatr Emerg Care 2001; 17: 435–7

    Article  PubMed  CAS  Google Scholar 

  79. Blaszak RT, Savage JA, Ellis EN. The use of short-acting nifedipine in pediatric patients with hypertension. J Pediatr 2001; 139: 34–7

    Article  PubMed  CAS  Google Scholar 

  80. Egger DW, Deming DD, Hamada N, et al. Evaluation of the safety of short-acting nifedipine in children with hypertension. Pediatr Nephrol 2002; 17: 35–40

    Article  PubMed  Google Scholar 

  81. Sinaiko AR, Daniels SR. The use of short acting nifedipine in children with hypertension: another example of need for comprehensive drug testing in children. J Pediatr 2001; 39: 7–9

    Google Scholar 

  82. Calvetta A, Martino S, Von Vigier RO, et al. What goes up must immediately come down! Which indication for short acting nifedipine in children with arterial hypertension? Pediatr Nephrol 2003; 18: 1–2

    Article  PubMed  CAS  Google Scholar 

  83. Blowey DL, Moncica I, Scolnik D, et al. The pharmacokinetics of extended release felodipine in children. Eur J Clin Pharmacol 1996; 50: 147–8

    Article  PubMed  CAS  Google Scholar 

  84. Moncica I, Oh PI, ul Qamar I, et al. A crossover comparison of extended release felodipine with prolonged action nifedipine in hypertension. Arch Dis Child 1995; 73: 154–6

    Article  PubMed  CAS  Google Scholar 

  85. McEvoy GK, editor. AHFS drug information 1996. Bethesda (MD): American Society of Health System Pharmacists, 1996: 1295–7

    Google Scholar 

  86. Fitton A, Benfield P. Isradipine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in cardiovascular disease. Drugs 1990; 40: 31–74

    Article  PubMed  CAS  Google Scholar 

  87. Sandoz Pharmaceuticals. DynaCirc, isradipine [product information]. Hanover (NJ): Sandoz Pharmaceuticals, 1998

    Google Scholar 

  88. Hanson L. Isradapine: a profile in essential hypertension. Acta Anaesthesiol Scand 1993; 37 Suppl.: 26–8

    Article  Google Scholar 

  89. Brogden RN, Sorkin EM. Isradipine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension. Drugs 1995; 49: 618–49

    Article  PubMed  CAS  Google Scholar 

  90. MacDonald JL, Johnson CE, Jacobson P. Stability of isradipine in an extemporaneously compounded oral liquid. Am J Hosp Pharm 1994; 51: 2409–11

    PubMed  CAS  Google Scholar 

  91. Johnson CE, Jacobson PA, Song MH. Isradipine therapy in hypertensive pediatric patients. Ann Pharmacother 1977; 31: 704–7

    Google Scholar 

  92. Strauser LM, Groshong T, Tobias JD. Initial experience with isradipine for the treatment of hypertension in children. South Med J 2000; 93: 287–93

    PubMed  CAS  Google Scholar 

  93. Murdoch D, Heel RC. Amlodipine: a review of its pharmcaodynamic and pharmacokinetic properties and therapeutic use in cardiovascular disease. Drugs 1991; 41: 478–501

    Article  PubMed  CAS  Google Scholar 

  94. Haria M, Wagstaff AJ. Amlodipine: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995; 50: 560–86

    Article  PubMed  CAS  Google Scholar 

  95. Clavijo GA, de Clavijo IV, Weart CW. Amlodipine: a new calcium antagonist. Am J Hosp Pharm 1994; 51: 59–68

    PubMed  CAS  Google Scholar 

  96. Lahar MS, Kelly JG, Doyle GD, et al. Pharmacokinetics of amlodipine in renal impairment. J Cardiovasc Pharmacol 1988; 12Suppl. 7: 60–3

    Article  Google Scholar 

  97. Pfammatter JP, Clericetti-Affolter C, Truttmann AC, et al. Amlodipine once-daily in systemic hypertension. Eur J Pediatr 1998; 157: 618–21

    Article  PubMed  CAS  Google Scholar 

  98. Khattak S, Rogan JQW, Saunders EF, et al. Efficacy of amlodipine in pediatric bone marrow transplant patients. Clin Pediatr 1998; 37: 31–6

    Article  CAS  Google Scholar 

  99. Flynn JT, Smoyer WE, Bunchman TE. Treatment of hypertensive children with amlodipine. Am J Hypertens 2000; 13: 1061–6

    Article  PubMed  CAS  Google Scholar 

  100. Rogan JW, Lyszkiewicz DA, Blowey D, et al. A randomized prospective crossover trial of amlodipine in pediatric hypertension. Pediatr Nephrol 2000; 14: 1083–7

    Article  PubMed  CAS  Google Scholar 

  101. Nahata MC, Morosco RS, Hipple TF. Stability of amlodipine besylate in two liquid dosage forms. J Am Pharm Assoc 1999; 39: 375–7

    CAS  Google Scholar 

  102. Frishman WH. New therapeutic modalities in hypertension: focus on a new calcium channel antagonist: nicardipine. J Clin Pharmacol 1989; 29: 481–7

    PubMed  CAS  Google Scholar 

  103. IV Nicardipine Study Group. Efficacy and safety of intravenous nicardipine in the control of postoperative hypertension. Chest 1991; 99: 393–8

    Article  Google Scholar 

  104. Lambert CR, Hill JA, Nichols WM, et al. Coronary and systemic hemodynamic effects of nicardipine. Am J Cardiol 1985; 55: 652–6

    Article  PubMed  CAS  Google Scholar 

  105. Halpern NA, Goldberg M, Neely C, et al. Postoperative hypertension: a multicenter, prospective, randomized comparison between intravenous nicardipine and sodium nitroprusside. Crit Care Med 1992; 20: 1637–43

    Article  PubMed  CAS  Google Scholar 

  106. Treluyer JM, Hubert P, Jouvet P, et al. Intravenous nicardipine in hypertensive children. Eur J Pediatr 1993; 152: 712–4

    Article  PubMed  CAS  Google Scholar 

  107. Gouyon JB, Geneste B, Semama DS, et al. Intravenous nicardipine in hypertensive preterm infants. Arch Dis Child Fetal Neonatal Ed 1997; 76: F126–7

    Article  PubMed  CAS  Google Scholar 

  108. Milou C, Debuche-Benouachkou V, Semama DS, et al. Intravenous nicardipine as a first-line antihypertensive drug in neonates. Int Care Med 2000; 26: 956–8

    Article  CAS  Google Scholar 

  109. Michael J, Groshong T, Tobias JD. Nicardipine for hypertensive emergencies in children with renal disease. Pediatr Nephrol 1998; 12: 40–2

    Article  PubMed  CAS  Google Scholar 

  110. Tenney F, Sakarcan A. Nicardipine is a safe and effective agent in pediatric hypertensive emergencies. Am J Kidney Dis 2000; 35: 1–3

    Article  Google Scholar 

  111. Flynn JT, Mottes TA, Brophy PD, et al. Intravenous nicardipine for treatment of severe hypertension in children. J Pediatr 2001; 139: 38–43

    Article  PubMed  CAS  Google Scholar 

  112. Tobias JD, Lowe S, Deshpande JK. Nicardipine: perioperative applications in children. Paediatr Anaesth 1995; 5: 171–6

    Article  PubMed  CAS  Google Scholar 

  113. Tobias JD, Hersey S, Mencio GA, et al. Nicardipine for controlled hypotension during spinal surgery. J Pediatr Ortho 1996; 16: 370–3

    Article  CAS  Google Scholar 

  114. Tobias JD. Nicardipine to control mean arterial pressure after cardiothoracic surgery in infants and children. Am J Therapeutics 2001; 8: 3–6

    Article  CAS  Google Scholar 

  115. Nishikawa T, Omote K, Namiki A, et al. The effects of nicardipine on cere-brospinal fluid pressure in humans. Anesth Analg 1986; 65: 507–10

    Article  PubMed  CAS  Google Scholar 

  116. Levene MI, Gibson NA, Fenton AC, et al. The use of a calcium channel blocker, nicardipine, for severely asphyxiated newborn infants. Dev Med Child Neurol 1990; 32: 567–74

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The author would like to thank Ms Ann Elliott for her secretarial help in the preparation of this manuscript. No sources of funding were used to assist in the preparation of this review. The author has no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Division of Pediatric Nephrology, Loma Linda Children’s Hospital, Loma Linda, 11175 Campus Street - Coleman Pavilion, California, 92354, USA

    Shobha Sahney

Authors
  1. Shobha Sahney
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shobha Sahney.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sahney, S. A Review of Calcium Channel Antagonists in the Treatment of Pediatric Hypertension. Pediatr-Drugs 8, 357–373 (2006). https://doi.org/10.2165/00148581-200608060-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00148581-200608060-00004

Keywords

Search

Navigation